From Joe Burnett, President & CEO:
On the heels of reporting our Second Quarter results, I am delighted to share with our customers and partners some key highlights:
- ClearPoint Prism™ Neuro Laser Therapy System: We continue to expand our limited market release to new centers in the U.S., and are receiving very positive feedback with each procedure. Preliminary data from the ongoing prospective trial in Sweden will be presented from the podium at ESSFN this fall in Stockholm. If you're interested in seeing the Prism system, please stop by our booth at the CNS Tumor Symposium, or the CNS Annual Meeting in September.
- Biologics and Drug Delivery: This segment of our business has become our fastest growing with 50+ partners to date. Our team is excited to support ongoing and new pre-clinical and clinical trials in the coming months. Just this week, our partner Aspen Neuroscience announced FDA clearance of its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001, a personalized (autologous) cell therapy to treat Parkinson’s Disease by replacing lost dopamine neurons.
- Innovation Pipeline: Our R&D teams have been hard at work expanding our current portfolio in partnership with our physician and pharma customers. In the second half of 2023 we plan to execute as many as five FDA submissions directly, or through partnerships, for new products that we believe will help improve outcomes, reduce procedure times and lower the cost of delivering care.
- New Manufacturing Facility: I'm happy to report that we have completed construction on the clean room at our new ~20,000 square foot facility in Carlsbad, California, ahead of schedule. We believe we will be able to manufacture products there in the coming months, and plan to wind down our operations in Irvine by the end of 2023.
Thank you for being part of our ClearPoint mission to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders. As always, feel free to reach out directly to me with any questions.
Three-year-old Suffering from AADC Deficiency Receives ClearPoint-Empowered Gene Therapy at the Policlinico Umberto I in Rome
ClearPoint's European team is pleased to have supported the first commercial gene therapy procedure in Italy to treat AADC Deficiency. Neurosurgeons at Policlinico Umberto I in Rome used our SmartFlow® Cannula, together with the ClearPoint Navigation Platform under MRI guidance to deliver the therapy.
The procedure was described at a Press Conference organized by the Azienda Ospedaliero-Universitaria Policlinico Umberto I and Sapienza University of Rome.
Osservatorio Malattie Rare (OMaR), a journalistic agency in Europe dedicated to rare disease and rare cancers, conducted a Video Interview with the patient's father Sebastiano, offering a first-hand account of the remarkable story of the 3-year-old AADC Deficiency patient's journey.
Upcoming Abstracts Featuring ClearPoint Technology
Please see below academic abstract presentations featuring the ClearPoint platform to be presented at upcoming major Neurosurgery meetings in the U.S. and Europe:
Intraoperative Features of Real-time Magnetic Resonance Imaging of Multi-site Direct Convective Delivery of Gene Therapy in Huntington's Disease
Interactive Poster Presentation by James Bradley Elder, MD - Ohio State University
Congress of Neurological Surgeons (CNS) Annual Meeting - Washington, DC
September 12, 2023 at 6:00 PM
Laser interstitial thermal therapy using an uncooled laser catheter in a diagnostic MR suite
Podium Presentation by Hjálmar Bjartmarz, MD - Skåne University Hospital
European Society for Stereotactic and Functional Neurosurgery (ESSFN) Congress - Stockholm, Sweden
September 28, 2023 at 2:20 PM
Automatic Nonhuman Primate Brain Segmentation for Convection-Enhanced Drug Delivery
Digital Poster by Chen Li, PhD - ClearPoint Neuro
Congress of Neurological Surgeons (CNS) Annual Meeting - Washington, DC
September 9-13, 2023
Visit ClearPoint Neuro at Booth Booth 606 on September 9-13 for the 2023 CNS Annual Meeting
ClearPoint Neuro will be exhibiting at the 2023 Congress of Neurological Surgeons (CNS) Annual Meeting in Washington D.C. from September 9th - 13th.
Schedule a meeting at Booth 606 to check out our latest innovations: ClearPoint Prism™ Neuro Laser Therapy System, ClearPoint Software v.2.1, and the ClearPoint Maestro Brain® Model.
Visit ClearPoint Neuro at Booth 09 on September 27-30 for the 2023 ESSFN Biennial Meeting
ClearPoint Neuro will be exhibiting at the 2023 European Society for Stereotactic & Functional Neurosurgery (ESSFN) Biennial Meeting in Stockholm, Sweden from September 27th - 30th.
Stop by Booth 09 to meet members of our team and learn more about our portfolio of innovative neurosurgical technologies and educational resources.
Check Out the ClearPoint Prism™ Neuro Laser Therapy System at the CNS Tumor Section Symposium
We are first-time exhibitors at the 2023 Tumor Section Symposium: Brain in Washington D.C. from September 8th - 9th.
ClearPoint has supported over 850+ brain tumor procedures to-date including guiding biopsies, laser therapy, and cell & gene therapy in clinical trials. Stop by to learn about our innovative portfolio to support treatment of brain tumors.
ClearPoint is delighted to offer our 1st therapeutic device to support patients with brain tumors: ClearPoint Prism™ Neuro Laser Therapy System
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
Under the terms of the multi-year license agreement, UCB, a global biopharmaceutical leader, will utilize ClearPoint Neuro’s proprietary technology and services in connection with the research, development, and commercialization of UCB’s gene therapy products. ClearPoint Neuro will receive success-based milestone payments.
Join ClearPoint Neuro in Carlsbad, CA on October 10-12 at the Cell & Gene Meeting on the Mesa
Members from our Biologics and Drug Delivery team will be at the 2023 Annual Cell & Gene Meeting on the Mesa in Carlsbad, California from October 10th - 12th.
Our President and CEO, Joe Burnett, will also present on our technical and clinical achievements over the past 12 months in the areas of cell and gene therapy innovations live from the podium in Carlsbad and streamed for virtual attendees.
Meet Us in Brussels on October 24-27 at the 2023 ESGCT Annual Meeting
ClearPoint Neuro is proud to be a sponsor of the 2023 European Society of Gene & Cell Therapy (ESGCT) Annual Congress Meeting in Brussels, Belgium from October 24th - 27th.
Stop by our Booth 38 to learn about ClearPoint-enabled abstracts and sessions, and meet with our team to discuss your upcoming benchtop testing, preclinical studies, or clinical trial needs.
